SLC5A2 and hydrops fetalis: Patients treated with SGLT2 inhibitors experienced lower rates of hospitalizations for HF compared to those in the placebo group (RR: 0.77; 95% CI 0.69, 0.85; p < 0.001; I2:0%; Fig. 2), a result that was consistent in the time to first event analysis (HR: 0.75; 95% CI 0.67, 0.85; p < 0.01; I2:0%; Supplementary Fig. 1).